NorthWest Biotherapeutics Inc (NWBO)

[Evaluate]

Thanks Maverick! Good to know that I am coming along, and a long way at that.
Actually I have been "at it" here for longer than 6 months. My first investment in NWBO was Dec 2013. Not sure when I got hooked on NWBO iHub, but not too long into it.

So Maverick, did you get a chance to listen to the (28 minute) YouTube on Navid Malik (as I posted in 25115)? I thought it was interesting to get a feel for how he thinks:

June 21, 2013: www.youtube.com/watch?v=g4U0z19DacI

8:45: just entered 10 year bull market in biotech.
10:00: to investors: "what are you crying about"? and "you can make big returns in biotech during next 10 years".
12:20: Valuations of small biotechs.
13:30: Getting sufficient capital. Dislike coming back frequently for more money. Get fund managers involved.
14:40: Drive liquidity. Valuation upwards. Don't want to see SP drop during month after new major financing. Important: Good quality investor. Good new flow post new financing.
17:00: would be nice if there is a way for a company to start generating revenues to help offset costs of clinical trials {me: think HE}.
17:35: uncertainty of regulator approvals.
18:00: Dendreon/Provenge issues. Regulators step learning curve, including manufacturing.
18:40: Badge of honor from important financing sources. Other investors take note. Most of the investment money in UK & US = generous money: oftentimes they do not fully understand the sector nor the company (have not done full DD), and thus may rely on someone else with high credentials doing DD.
19:15: reimbursement part = scary. Need for high quality data.
20:00 consistency of financing into the business. Long haul investment cycle.
20:30: Consortium backing. Bring in institutional money. Venture funds. Generalist funds, including pension funds (deep pockets) ... bring company through to market access.
22:00: Valuation discrepancy based on geography.
23:30: Everyone can participate in most exciting area of medicine: deliver a cure, not just treating symptoms.
23:40: Out on the road speaking to some of the biggest fund managers in UK & Europe. Immune therapies. Third wave of biotech. Not decades away.
25:00 Antibodies.
25:40: manufacturing is critical. Decent cost of goods, otherwise market will not want it.
27:00: some biotech companies may wind up growing larger than AstraZeneka.